<DOC>
	<DOC>NCT01715415</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of ABT-450, ritonavir and ABT-267 (ABT-450/r/ABT-267; ABT-267 also known as ombitasvir) and ABT-333 (also known as dasabuvir) co-administered with ribavirin (RBV) in hepatitis C virus genotype 1 infected treatment-experienced adults.</brief_summary>
	<brief_title>A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>Females must be postmenopausal for at least 2 years or surgically sterile or practicing specific forms of birth control. Chronic hepatitis C, genotype 1 infection and HCV RNA level greater than 10,000 IU/mL at screening. Previous treatment failure of peginterferon and ribavirin (pegIFN and RBV). No evidence of liver cirrhosis. Positive screen for drugs or alcohol. Significant sensitivity to any drug. Use of contraindicated medications within 2 weeks of dosing. Certain predefined abnormal laboratory tests. Positive hepatitis B surface antigen or antihuman immunodeficiency virus antibody.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Treatment-Experienced</keyword>
	<keyword>Null responder</keyword>
	<keyword>Partial Responder</keyword>
	<keyword>Chronic Hepatitis</keyword>
	<keyword>Hepatitis C Genotype 1</keyword>
	<keyword>Interferon-Free</keyword>
	<keyword>Hepatitis C Virus</keyword>
	<keyword>Relapser</keyword>
	<keyword>Non responder</keyword>
	<keyword>Viekira Pak</keyword>
	<keyword>ombitasvir</keyword>
	<keyword>ribavirin</keyword>
	<keyword>ritonavir</keyword>
	<keyword>paritaprevir</keyword>
	<keyword>dasabuvir</keyword>
</DOC>